Barclays lowered the firm’s price target on GoodRx (GDRX) to $6 from $10 and keeps an Overweight rating on the shares post the Q3 report.
Daniel Grosslight, an analyst from Citi, maintained the Buy rating on GoodRx Holdings (GDRX – Research Report). The associated price ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback